ISSN: 2148-8274 / E-ISSN: 2587-0084
, Türk Üreme Tıbbı ve Cerrahisi
Dergisi

Turkish Journal of Reproductive Medicine and Surgery

Dernek Sitesi
Kayıtlı İndexler
ORİJİNAL ARAŞTIRMALAR

Polikistik Over Sendromlu Hastalarda Obezitenin IVF Sonuçları Üzerine Etkisi
Effect of Obesity on IVF Outcomes in Patients With Polycystic Ovary Syndrome
Received Date : 07 Dec 2020
Accepted Date : 31 Mar 2021
Available Online : 05 Apr 2021
Doi: 10.24074/tjrms.2020-80472 - Makale Dili: TR
TJRMS. 2021;5(1):6-10
ÖZET
Amaç: Ovulasyon bozuklukları infertilitenin yaygın nedenlerindendir ve polikistik over sendromu (PKOS) anovulasyon ile ilişkili en sık görülen durumdur. Obezite; hipertansiyon, kardiyovasküler hastalıklar, diyabet gibi kronik hastalıklara neden olabildiği gibi reproduktif sistem üzerine de olumsuz etkiler göstermektedir. Daha öncesinde yapılan çalışmalarda vücut kitle indeksinin IVF/ICSI sonuçları üzerine etkisi ile ilgili çelişkili sonuçlar bulunmaktadır. Polikistik over sendromu (PKOS) kadınların yaklaşık %5 inde görülmekte ve olguların yarıya yakını obezite sorunları yaşamaktadır. Obez PKOS lu hastalarda kilo verme 1. basamak tedavi seçeneğidir. Obez PKOS lu hastalarda vücut kitle indeksi ile IVF sonuçları arasındaki ilişki tam olarak anlaşılabilmiş değildir Bu çalışmanın amacı, polikistik over sendromu (PKOS) olan ve PKOS olmayan hastalarda vücut kitle indeksinin (BMI) in vitro fertilizasyon (IVF) / intrasitoplazmik sperm enjeksiyonu (ICSI) sonuçları üzerindeki etkisini değerlendirmektir. Gereç veYöntemler: Ege Üniversitesi Tüp Bebek Merkezinde gerçekleştirilen retrospektif bir kohort çalışmadır. Çalışmaya 35 yaş altı hastalar dahil edildi ve vücut kitle indekslerine göre dört gruba ayrıldı. PKOS ve PKOS olmayan hastalar arasında elde edilen oosit sayısı, metafaz 2 / metafaz 1 oranı, 2 pn embriyo ve klinik gebelik oranı farklı VKİ'ler arasında karşılaştırıldı. Bulgular: Obez PKOS'lu kadınlarda IVF / ICSI sonuçları değerlendirildiğinde, obez olmayan PKOS lu kadınlara göre daha düşük klinik gebelik oranı, alınan oosit sayısı ve 2 pn embriyo sayıları tespit edildi. Sonuç: PKOS hastalarında obezitenin, IVF/ICSI sonuçları üzerine olumsuz etkisi gözlendi.
ABSTRACT
Objective: Ovulation disorders are common causes of infertility, and polycystic ovary syndrome (PCOS) is the most common condition associated with anovulation. Obesity; It may cause chronic diseases such as hypertension, cardiovascular diseases and diabetes, as well as have negative effects on the reproductive system. There are conflicting results in previous studies regarding the effect of body mass index on IVF / ICSI results. Polycystic ovary syndrome (PCOS) is seen in approximately 5% of women and nearly half of the cases have obesity problems. Weight loss is the first line treatment option in patients with obese PCOS. The relationship between body mass index and IVF results in obese PCOS patients is not fully understood. The aim of this study is to assess the effect of body mass index (BMI) on outcomes of in vitro fertilization (IVF) / intracytoplasmic sperm injection (ICSI) among polycystic ovarian syndrome (PCOS) and non-PCOS patients. Material and Methods: This was a retrospective cohort study that was performed in the Ege University IVF Center. Patients who were under 35 years old were included in the study and were divided into four groups based on their BMI. The number of retrieved oocytes, metaphase 2/metaphase 1 ratio, 2 pn embryos and clinical pregnancy rate among PCOS and non-PCOS patients were compared between different BMIs. Results: IVF/ICSI outcomes in obese PCOS patients were evaluated lower rate of clinical pregnancy , number of retrieved oocytes and 2 pn embryos than in non-obese PCOS pregnancies. Conclusion: Obesity in PCOS patients led to poor outcomes of IVF/ICSI.
SITE.TEXT.RESOURCES
  1. Bozdag G, Mumusoglu S, Zengin D, Karabulut E, Yildiz BO. The prevalence and phenotypic features of polycystic ovary syn-drome: a systematic review and meta-analysis. Hum Reprod. 2016;31:2841-55. [Crossref]  [PubMed] 
  2. Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome. Fertil Steril. 2004;81(1):19-25. [Crossref] 
  3. Azziz R, Carmina E, Dewailly D, Diamanti-Kandarakis E, Escobar-Morreale HF, Futterweit W, et al.; Androgen Excess Society.Positions statement: criteria for defining polycystic ovary syndrome as a predominantly hyperandrogenic syndrome: an Androgen Excess Society guideline. J Clin Endocrinol Metab. 2006;91(11):4237-45. [Crossref]  [PubMed] 
  4. Taylor AE, McCourt B, Martin KA, et al. Determinants of abnorma gonadotropin secretion in clinically defined women with polycysti ovary syndrome. J Clin Endocrinol Metab. 1997;82: 2248-56. [Crossref]  [PubMed] 
  5. Pan JX, Zhang JY, Ke ZH, et al. Androgens are double-edged swords Induction and suppression of follicular development. Hormone (Athens). 2015;14:190-200. [Crossref]  [PubMed] 
  6. Bhide P, Homburg R. Anti-Müllerian hormone and polycystic ovar syndrome. Best Pract Res Clin Obstet Gynaecol. 2016;37:38-45. [Crossref]  [PubMed] 
  7. Stepto NK, Cassar S, Joham AE, Hutchison SK, Harrison CL, Goldstein RF, et al. Women with polycystic ovary syndrome have intrinsic insulin resistance on euglycaemic-hyperinsulaemic clamp. Hum Reprod. 2013;28(3):777-84. [Crossref]  [PubMed] 
  8. Pasquali R, Gambineri A, Pagotto U. The impact of obesity on reproductio in women with polycystic ovary syndrome. BJOG 2006;113: 1148-59. [Crossref]  [PubMed] 
  9. Tanbo T, Mellembakken J, Bjercke S, Ring E, Åbyholm T, Fedorcsak P. Ovulation induction in polycystic ovary syndrome. Acta Obstet Gynecol Scand. 2018;97(10):1162-7. doi: 10.1111/aogs.13395. [Crossref]  [PubMed] 
  10. Guh DP, Zhang W, Bansback N, Amarsi Z, Birmingham CL, Anis AH. The incidence of co-morbidities related to obesity and overweight: a systematic review and meta-analysis. BMC Public Health. 2009;9:88. [Crossref]  [PubMed]  [PMC] 
  11. Clinical Guidelines on the Identification, Evaluation, and Treatment of Overweight and Obesity in Adults-- The Evidence Report. Obes Res 1998;6:51S-209S.
  12. Franks S. Polycystic ovary syndrome. Arch Dis Child. 1997;77:89-90. [Crossref]  [PubMed]  [PMC] 
  13. Dafopoulos K, Venetis C, Pournaras S, Kallitsaris A, Messinis IE. Ovarian control of pituitary sensitivity of luteinizing hormone secretion to gonadotropin-releasing hormone in women with the polycystic ovary syndrome. Fertil Steril. 2009;92:1378-80. [Crossref]  [PubMed] 
  14. Pagán YL, Srouji SS, Jimenez Y, Emerson A, Gill S, Hall JE. Inverse relationship between luteinizing hormone and body mass index in polycystic ovarian syndrome: investigation of hypothalamic and pituitary contributions. J Clin Endocrinol Metabol. 2006;91:1309-16. [Crossref]  [PubMed] 
  15. Greisen S, Ledet T, Ovesen P. Effects of androstenedione, insulin and luteinizing hormone on steroidogenesis in human granulosa luteal cells. Hum Reprod. 2001;16:2061-5. [Crossref]  [PubMed]